|
|
 |
|
|
|
|
|
|
Department
|
Vascular Biology Program
|
|
Hospital Title
|
Director
Vascular Biology Program
|
|
Academic Title
|
Professor of Surgery
|
|
Phone
|
617-919-2207
|
|
Fax
|
617-730-0231
|
|
Email
|
Marsha Moses
|
|
Location
|
300 Longwood Avenue
Karp-12.214
Boston MA 02115
|
 |
 |
|
|
|
|
|
|
|
The Moses Lab has had a long-standing interest in identifying and characterizing the biochemical and molecular mechanisms underlying the regulation of angiogenesis during tumor progression, from the angiogenic switch through metastasis. Dr. Moses and her group have discovered a number of angiogenesis inhibitors, some of which are in pre-clinical development for use against a variety of cancers.
Significant efforts are also now underway in the lab to identify the genes, and the proteins that they encode, that are responsible for the 'angiogenic switch'. This critical checkpoint, during which time a tiny benign, avascular tumor acquires the vascular phenotype, is a prerequisite for subsequent tumor growth and progression. The Moses Lab has recently identified and validated a number of genes which are differentially expressed during the angiogenic switch and is currently developing molecular and biochemical interventions to regulate the switch by targeting some of these genes.
To complement these studies, Dr. Moses has established a Proteomics Initiative in her laboratory that has now led to the discovery of a panel of urinary cancer biomarkers that not only predict disease status and stage in cancer patients but are also sensitive and specific markers of disease progression and therapeutic efficacy of cancer drugs. A number of these urine tests are currently in clinical testing as potential cancer diagnostics and prognostics.
|
|
|
|
|
|
Marsha A. Moses received a PhD from Boston University and completed a National Institutes of Health postdoctoral fellowship at Children's Hospital Boston and MIT. Dr. Moses was elected to the Institute of Medicine of the National Academies of the United States in 2008. She is the recipient of a number of NIH and foundation grants. Additional awards and honors include the Cancer Research Foundation Award, the American Cancer Society Research Award and the CaPCURE Research Award, among others. Dr. Moses also received Harvard Medical School's A. Clifford Barger Mentoring Award in 2003. She is currently the Director (Interim) of the Vascular Biology Program at Children's Hospital Boston.
|
|
|
|
|
- Harper J., Yan L., Louriero R., Wu I., Fang J., D?Amore P., Moses M.A. (2007) Repression of VEGF expression by the zinc finger transcription factor ZNF24. Cancer Res., 67(18):8736-41.
- Pories S.E., Zurakowski D, Roy R, Lamb C.C., Raza S, Exarhopoulos A, Scheib R.G., Schumer S, Lenahan C, Borges V, Louis G.W., Anand A, Isakovich N, Hirschfield-Bartek J, Wewer U, Lotz M.M., Moses M.A. (2008) Urinary metalloproteinases: noninvasive biomarkers of breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev., 17(5);1034-42.
- Smith E.R., Manfredi M., Scott R.M., Black P., Moses M.A. (2007) A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery, 60(6):E1148-9.
- Fernandez, C.A., Butterfield, C, Jackson, G, Moses, M.A., (2003) Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of TIMP-2: Loop 6 is a novel angiogenesis inhibitor. J. Biol. Chem., 278:40989-40995.
- Moses MA, Harper J, Folkman J. (2006) Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med. Jun 15;354(24):2621-2.
|
|
|
|
|
|
|
